real-world practice 11, 12 due, in part, to potential cardiorenal interactions. [12] [13] [14] Over a decade after the RALES trial, the degree of clinical benefit derived from MRA, particularly spironolactone, remains uncertain in patients with AF and HF on contemporary optimal HF therapy. Although the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) trial, which assessed the impact of eplerenone in New York Heart Association (NYHA) class II patients with HF, included 30% of patients with AF, 15 no prospective randomized trial has focused on MRA in patients with AF and HF. We, therefore, sought to assess the impact of MRA on cardiovascular mortality in the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial, a study that exclusively enrolled patients with AF and systolic ventricular dysfunction.
Methods

Study Population
The AF-CHF trial randomized 1376 patients with HF, systolic dysfunction, and a recent history of AF to rhythm versus rate control strategies. The study protocol has been previously described. 16, 17 In short, inclusion criteria consisted of a history of electrocardiographically documented AF, left ventricular ejection fraction (LVEF) ≤35%, and NYHA class II to IV symptoms within 6 months of randomization, or class I symptoms if the LVEF was ≤25% or if the patient was hospitalized for HF in the previous 6 months. Patients were excluded if they were expected to live <1 year, had persistent AF for >12 months, were candidates for heart transplantation within 6 months, had decompensated HF in the 48 hours before randomization, or had renal failure requiring dialysis. The study protocol was approved by each center's institutional review board, and all patients provided written informed consent.
Renal Function
Baseline serum creatinine levels were available in 1365 patients (99.2%). Renal function was also evaluated according to the estimated glomerular filtration rate (eGFR), using categories of CKD as follows 18 
Pharmacological Therapy
Recommended pharmacological therapy included anticoagulants, the maximum tolerated dose of β-blockers, and angiotensinconverting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) for all patients. As per current guidelines, spironolactone (12.5-50 mg/day) was recommended during the randomization period in patients receiving a loop diuretic with NYHA functional class III or IV symptoms, a serum creatinine ≤2.5 mg/dL, and a serum potassium ≤5.0 mEq/L. The assigned treatment strategy for AF (ie, rate versus rhythm control) was initiated immediately after randomization. Patients assigned to rhythm control systematically received amiodarone as the initial antiarrhythmic drug. Targets for rate control were heart rates <80 beats per minute at rest and <110 beats per minute during 6-minute walk tests. Recommended β-blockers were carvedilol, bisoprolol, and metoprolol. Clinicians were instructed to provide optimal medical therapy.
Outcomes
Patients were seen at 3 weeks and 4 months, followed by visits every 4 months through 4 years and then every 6 months until 6 years. As in the main intention-to-treat analysis, 17 the primary outcome for the current study was cardiovascular death. Secondary outcomes included presumed arrhythmic death, all-cause mortality, and worsening heart failure. A presumed arrhythmic death was defined as a sudden cardiovascular death occurring <1 hour after the onset of symptoms and deemed not be because of another cardiovascular cause, such as an ischemic event. Sudden deaths during sleep, unwitnessed deaths, and unmonitored deaths in previously stable patients were presumed to be arrhythmic in origin. All events were classified by an independent adjudicating committee blinded to the treatment assignment.
Statistical Analysis
Continuous variables were presented as mean±SD or median and interquartile range (Q1-Q3) according to their distribution and categorical variables as frequencies and percentages. Baseline variables were assessed overall and according to whether or not patients received MRA. Two-group comparisons were made using independent Student t, Mann-Whitney, or χ 2 tests, where appropriate. After verifying proportionality assumptions, univariable and multivariable Cox regression models were created for each of the 4 outcomes, ie, cardiovascular mortality, presumed arrhythmic death, all-cause mortality, and worsening heart failure. On the basis of substantive knowledge, the following exposure variables were included in all multivariable models, regardless of their statistical associations: AF-CHF treatment assignment (rate versus rhythm control), MRA therapy as a time-dependent variable, NYHA functional class, LVEF, creatinine, potassium, and use of a diuretic at baseline. Remaining baseline variables were assessed in univariable Cox regression models, and those significant at the 0.2 level were included in backward multivariable models and retained if the P value was <0.20. Variables considered for such models included patient demographics (eg, age at randomization, sex, body mass index), AF and HF history (eg, paroxysmal versus persistent AF, time since initial diagnosis of AF, hospitalization for HF within 6 months of randomization), comorbidities (eg, coronary artery disease, prior myocardial infarction, hypertension, diabetes mellitus requiring pharmacological therapy, prior stroke), medications (eg, ACE inhibitors or ARBs, lipid-lowering drug, oral anticoagulant, digoxin, β-blockers, antiarrhythmic agents), physical examination (eg, diastolic blood pressure, heart rate, peripheral edema), additional cardiac parameters (eg, QRS width, left atrial diastolic dimension, degree of mitral regurgitation, cardiomegaly, pulmonary congestion by chest x-ray), and blood tests (eg, serum sodium level). Digoxin, β-blockers, and antiarrhythmic agents were, along with MRA, modeled as time-dependent variables to account for changes over the course of the study. For each time-to-event outcome, Kaplan-Meier product limit curves were plotted according to whether patients received an aldosterone antagonist at baseline or not, with comparisons by log-rank tests.
In a second approach to multivariable modeling to assess the impact of MRA therapy on the 4 time-to-event outcomes, a propensity score was generated to adjust for baseline imbalances. This was derived from a nonparsimonious logistic regression model, with aldosterone antagonist therapy as the outcome variable. The following variables were included in the propensity score: treatment, age, sex, race, NYHA class, history of cerebrovascular event, LVEF, primary classification of AF, time since first diagnosis of AF, QRS width, left atrial diameter, hospitalization for HF within 6 months, digoxin, ACE inhibitors or ARBs, lipid-lowering drug, β-blocker, potassium level, and proportion of time spent in sinus rhythm. The propensity score was modeled as a continuous variable in multivariable Cox regression analyses that included MRA as a time-dependent variable. In a subgroup analysis of 183 patients in whom serial serum creatinine and potassium levels were available, similar models were created but with creatinine and potassium as time-dependent variables.
Because multivariable regression approaches without and with propensity scores yielded similar results for all outcomes, the former analyses are presented. All statistical analyses were performed using SAS software version 9.2 (SAS Institute Inc, Cary, NC). For all analyses, P<0.05 was considered statistically significant. The authors had full access to the data and take responsibility for its integrity.
Results
Baseline Characteristics
All 1376 patients randomized in the AF-CHF trial were included. Table 1 . As expected, patients receiving MRA had lower LVEFs, larger left atrial dimensions, more cardiomegaly and peripheral edema, a higher NYHA functional class, and were more frequently hospitalized for HF within 6 months before randomization. They also more frequently had persistent AF, had longer durations of AF, wider QRS complexes, more moderate renal dysfunction, and lower blood pressure. Patients on MRAs at baseline more often received ACE inhibitors or ARBs, diuretics, and digoxin but were less frequently prescribed lipid-lowering drugs.
Cardiovascular Outcomes and MRAs
Over the course of the study, 445 patients died, 357 of which were from cardiovascular causes, with 159 deaths of presumed arrhythmic cause. In addition, a total of 402 episodes qualified as worsening HF. In multivariable analyses, MRAs had no appreciable impact on episodes of worsening HF (hazard ratio [ 
Cardiovascular Outcomes and Renal Function
In multivariable analyses, a higher baseline creatinine level was not associated with an increase in all-cause mortality or cardiovascular mortality. However, the risk of worsening HF increased with the serum creatinine level (HR, 1.09 per 27 μmol/L [0.3 mg/dL]; 95% CI [1.03-1.16]; P=0.0026). Model fits were comparable with creatinine and eGFR, such that the former was retained in multivariable analyses. Baseline potassium levels were not independently associated with mortality (total or cardiovascular), worsening HF, or arrhythmic deaths. However, in the small subset of patients in whom follow-up potassium levels were available (N=183; all from Montreal, Canada, or Denmark), lower serum potassium levels on follow-up were associated with an increase in cardiovascular mortality (P=0.003).
Concomitant HF Therapy
In multivariable analyses, digoxin was not associated with allcause mortality or with worsening HF but was associated with a nonstatistically significant increased likelihood of presumed arrhythmic death (HR, 1.5; 95% CI [1.0-2.4]; P=0.07). In contrast, β-blockers were associated with a 40% reduction in total mortality (HR, 0.6; 95% CI [0. 5- 
Discussion
The AF-CHF trial provided a unique opportunity to assess the impact of MRAs on outcomes in patients with AF and HF, with nearly 45% of the study population receiving such therapy. MRAs were associated with a 1.4-fold increase in total and cardiovascular mortality in multivariable analyses. This was driven by a 2-fold increased risk of death of presumed arrhythmic cause, with no effect on nonarrhythmic death or hospitalizations for worsening heart failure. Importantly, the prescribed MRA was almost exclusively spironolactone, because eplerenone was introduced in the market after a vast majority of patients had been randomized. Although MRAs were recommended in patients with NYHA class III or IV symptoms, management decisions remained at the discretion of the treating physician. Notably, the functional status may have improved between the initial prescription of an MRA and enrolment in AF-CHF, explaining the discrepancy between the NYHA functional class distribution 6 months before randomization and at randomization.
Although multivariable regression models were not specifically designed to address the impact of other forms of heart failure therapy, β-blockers were associated with the expected reduction in total, cardiovascular, and arrhythmic mortality. The nonsignificant trend between digoxin and presumed arrhythmic deaths may be consistent with the results of a substudy of the DIG [Digitalis Intervention Group] trial, in which serum potassium levels <4 mEq/L predicted increased mortality in patients with CKD. 19 The interplay among digoxin, renal failure, and serum potassium levels merits further study.
Underlying reasons for the observed increased mortality, particularly sudden arrhythmic deaths, in patients with AF and HF receiving spironolactone remain speculative and may involve an interplay among the higher prevalence of renal dysfunction, greater use of digoxin and antiarrhythmic agents, potassium imbalances, cardiac structural or functional anomalies, and particularities related to the type of MRA prescribed.
In this AF-CHF substudy, renal dysfunction was found to be highly prevalent. CKD is associated with multiple comorbid conditions and markers of cardiovascular risk. In comparison with patients included in the EMPHASIS-HF trial, 15 ). [20] [21] [22] Lower renal function combined with different comorbidities could increase the likelihood of cardiorenal interactions in the context of multiple inhibitors of the renin-angiotensin-aldosterone system. Atrial fibrillation begets CKD, and vice versa. 9 Common pathophysiological mechanisms are thought to include inflammation, oxidative stress, and activation of the renin-angiotensinaldosterone system. [23] [24] [25] [26] [27] [28] [29] In addition, undesirable effects of AF may be further compounded by coexisting HF. For example, left atrial remodeling associated with AF leads to mitral annular dilatation and mitral regurgitation. Consequently, cardiac output and renal perfusion may be further reduced, lessening the benefits of MRAs.
Consistent with our findings, a large population-based study 11 demonstrated higher mortality after increases in prescriptions of spironolactone after publication of the RALES trial. 10 The increased mortality was thought to be mediated by associated hyperkalemia.
11-14 β-blocker prescriptions were also increasing during the same period, which may be of relevance for certain cardiorenal interactions. 13, 14 Potassium levels are influenced by complex interactions involving comorbidities (namely diabetes mellitus and renal disease) and concomitant therapies. 12, 13 Interestingly, in the subgroup of 183 patients in whom follow-up potassium data were obtained, lower rather than higher potassium levels were associated with increased cardiovascular mortality. This relationship has been recently observed by others as well. 19 It may be speculated that hypokalemia is more likely to be undertreated in patients with CKD (as in the AF-CHF population), particularly when MRAs are prescribed, resulting in a higher incidence of sudden death. It may be reasonable, therefore, to target potassium levels of 4.0, as per recent recommendations. 19 Importantly, serum potassium and renal function were closely monitored in all MRA trials, underscoring important differences with realworld care.
Limitations of this post hoc analysis include the nonrandomized allocation of MRAs. Attendant biases were thoroughly addressed using 2 complementary statistical approaches: multivariable analyses that adjusted for baseline imbalances and potential confounders, and propensity-adjusted regression analyses. The 2 approaches yielded congruent results. Although multivariable analyses do not control for unmeasured variables, our findings cannot be explained by baseline differences in observed HF-related variables. Importantly, MRA-treated patients did not experience higher rates of worsening HF or nonarrhythmic deaths in adjusted analyses, suggesting that multivariable models adequately controlled for imbalances in unmeasured HF-related patient characteristics. Increases in creatinine or potassium levels over time may have influenced the choice of medical therapy. Whereas baseline levels were systematically collected in all participants and included in multivariable analyses, data on follow-up creatinine and potassium levels were available only in a subgroup of 183 patients. Importantly, MRA use was modeled as a timedependent variable, such that patient time was attributed to the exposure category under observation.
Our findings may not be generalizable to MRAs other than spironolactone. Substantial differences in the pharmacological properties of spironolactone and eplerenone 30 may be of clinical relevance. Spironolactone has 3 active metabolites and a much longer half-life than eplerenone, which has no active metabolites. Eplerenone has a much lower affinity for androgen, progesterone, and glucocorticoïd receptors than spironolactone, which enhances tolerability and may improve glucose control. 31 Spironolactone seems to increase cortisol levels in comparison with eplerenone, 31 and higher cortisol levels could predict cardiac events in HF. 32 Finally, it also seems that eplerenone produces more consistent inhibition of some nongenomic effects of aldosterone, such as coronary vasoconstriction and increased systemic vascular resistance. 33 In the RALES trial (N=1663), which compared spironolactone with placebo, only 11% received β-blockers. 10 This is in stark contrast to 80% of patients in AF-CHF. This may be relevant to our findings, because some of the benefits of β-blockers and MRAs are produced by similar mechanisms. 34 The proportion of patients enrolled in the RALES trial (spironolactone versus placebo) with AF cannot be deduced from the published data. In contrast, AF was present in ≈30% of the study population in EMPHASIS-HF. 15 In this trial, there was no detectible interaction between AF and the impact of eplerenone on the primary outcome of cardiovascular death or heart failure-related hospitalization. These disparate findings may reflect the fact that different MRAs were used in AF-CHF (ie, spironolactone) and EMPHASIS-HF (ie, eplerenone). Furthermore, the rate of sudden death was lower in EMPHASIS-HF (ie, 5%) compared with AF-CHF (ie, >10%). In addition, potassium and creatinine levels were closely monitored in EMPHASIS-HF, and a higher proportion of patients received implantable cardioverter-defibrillators.
Conclusions
In our analyses of patients with HF and AF, MRAs (predominantly spironolactone) were associated with increased cardiovascular and total mortality, driven by an increased incidence of sudden death. Our results should be considered hypothesis generating and require confirmation by prospective randomized clinical trials. Importantly, these findings may not be generalized to eplerenone and newer, more AF-CHF indicates Atrial Fibrillation and Congestive Heart Failure; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; ACE, angiotensin-converting-enzyme; ARB, angiotensin-receptor blocker; HF, heart failure.
The following additional variables were associated with P values ≤0.20 in univariable analyses and were, therefore, considered in the multivariable model: age at randomization, body mass index, coronary artery disease, diabetes mellitus requiring medication, transient ischemic attack, stroke, or intracranial bleed, oral anticoagulant, antiplatelet agent, left atrial dimension (mm), serum sodium, hospitalization for HF in the 6 mo before randomization, peripheral edema, rales, radiological signs of pulmonary congestion.
*After backward selection of variables. selective, MRAs. Pathophysiological mechanisms remain to be elucidated and may include cardiorenal interactions and potassium imbalances. Close monitoring of serum potassium and renal function seems warranted in patients with AF and HF who receive MRAs. Prospective studies reassessing combinations of currently recommended HF therapy are required to optimize the pharmacological management of patients with AF and HF.
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